Incidence of hematological malignancies in Europe by morphological subtype: results of the HAEMACARE project

Milena Sant, Claudia Allemani, Carmen Tereanu, Roberta De Angelis, Riccardo Capocaccia, Otto Visser, Rafael Marcos-Gragera, Marc Maynadié, Arianna Simonetti, Jean-Michel Lutz and Franco Berrino
This article has an Erratum 117(12):3477


Changing definitions and classifications of haematological malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest WHO classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardised incidence rates for European HMs according to these groupings, estimated from 66,371 lymphoid malignancies (LMs) and 21,796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardised incidence rates were 24.5 (per 100,000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.62), small B-cell lymphocytic lymphoma/chronic lymphatic leukaemia (3.79), diffuse B-cell lymphoma (3.13) and Hodgkin lymphoma (2.41). The commonest MMs were acute myeloid leukaemia (2.96), other myeloproliferative neoplasms (1.76) and myelodysplastic syndrome (1.24). Unknown morphology LMs were commonest in Northern Europe (7.53); unknown morphology MMs were commonest in Southern Europe (0.73). Overall incidence was lowest in Eastern Europe, and lower in women than men. For most LMs, incidence was highest in Southern Europe; for MMs incidence was highest in UK & Ireland. Differences in diagnostic and registration criteria are an important cause of incidence variation, however different distribution of HM risk factors also contributes. The quality of population-based HM data needs further improvement.

  • Submitted May 3, 2010.
  • Accepted June 17, 2010.